LCMT2

Across TCGA pan-cancer cohorts, LCMT2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LCMT2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LCMT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCMT2 expression acts as an unfavorable survival marker.

LUAD and HNSC are the cancer types where LCMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.250	0.733	.024	6	view →
HNSC	DFS	Quartile	II,III,IV	0.897	1.000	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LCMT2–LUAD (DFS)

Open the LUAD breakdown →